Literature DB >> 31698044

Coexistence of Clostridioides difficile and Staphylococcus aureus in gut of Iranian outpatients with underlying inflammatory bowel disease.

Masoumeh Azimirad1, Marcela Krutova2, Hedieh Balaii3, Mansoor Kodori1, Shabnam Shahrokh3, Omid Azizi4, Abbas Yadegar5, Hamid Asadzadeh Aghdaei6, Mohammad Reza Zali3.   

Abstract

Clostridioides difficile and Staphylococcus aureus are two well-known pathogens both causing hospital- and community-acquired infections. However, their intestinal coexistence was not well investigated in inflammatory bowel disease (IBD). Herein, we explored the prevalence of C. difficile, S. aureus and their coexistence in the gut of Iranian patients with IBD. Fecal and colon specimens were obtained from 70 outpatients with underlying IBD, and investigated for the presence of C. difficile and S. aureus. C. difficile isolates were characterised by CE-ribotyping. PCR was used for detection of toxin-encoding genes of C. difficile and S. aureus isolates. The antimicrobial susceptibility testing of C. difficile and S. aureus isolates were examined by agar dilution and Kirby-Bauer disk diffusion methods, respectively. Totally, C. difficile and S. aureus were detected in only 5.7% and 15.8% of IBD flares. Coexistence of C. difficile and S. aureus was detected in 5.7% of IBD flares. Two different C. difficile ribotypes including RT 126 and RT 017 were identified showing toxin profiles of tcdA+B+/cdtA+B+ and tcdA+B+, respectively. In S. aureus isolates, only positivity for the presence of sea enterotoxin was detected. C. difficile isolates were susceptible to metronidazole, ceftazidime and fidaxomicin. The highest resistance of S. aureus isolates was observed against penicillin (92.3%), following amoxicillin-clavulanate (38.5%) and amikacin (30.8%). Our findings demonstrated that patients with IBD flare are more sensitive to acquire coinfection of C. difficile and S. aureus than remission. However, more robust data is required to study the crosstalk between these enteric infections and their clinical relevance in patients with IBD flare.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridioides difficile; Coexistence; Inflammatory bowel disease; Outpatient setting; Staphylococcus aureus

Year:  2019        PMID: 31698044     DOI: 10.1016/j.anaerobe.2019.102113

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  6 in total

1.  Blastocystis and Clostridioides difficile: Evidence for a Synergistic Role in Colonization Among IBD Patients with Emphasis on Ulcerative Colitis.

Authors:  Masoumeh Azimirad; Sara Mohammad Ali Gol; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Hamid Asadzadeh Aghdaei; Shabnam Shahrokh; Hedieh Balaii; Amir Sadeghi; Mohammad Reza Zali
Journal:  Turk J Gastroenterol       Date:  2021-06       Impact factor: 1.852

2.  Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease.

Authors:  Masoumeh Azimirad; Abbas Yadegar; Fatemeh Gholami; Shabnam Shahrokh; Hamid Asadzadeh Aghdaei; Gianluca Ianiro; Hidekazu Suzuki; Giovanni Cammarota; Mohammad Reza Zali
Journal:  J Inflamm Res       Date:  2020-09-18

3.  Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study.

Authors:  Masoumeh Azimirad; Marcela Krutova; Abbas Yadegar; Shabnam Shahrokh; Meysam Olfatifar; Hamid Asadzadeh Aghdaei; Warren N Fawley; Mark H Wilcox; Mohammad Reza Zali
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

4.  Frequency of toxin genes and antibiotic resistance pattern of Clostridioides difficile isolates in diarrheal samples among hospitalized patients in Hamadan, Iran.

Authors:  Leili Shokoohizadeh; Fatemeh Alvandi; Abbas Yadegar; Masoumeh Azimirad; Seyed Hamid Hashemi; Mohammad Yousef Alikhani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021

5.  Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease.

Authors:  Mohammad Abdehagh; Masoumeh Azimirad; Hamidreza Houri; Banafsheh Nadalian; Fahimeh Azimirad; Meysam Olfatifar; Ome Kolsoum Nasir Shoeibi; Abbas Yadegar; Shabnam Shahrokh; Mehran Mahdavi Roshan; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  BMC Infect Dis       Date:  2021-10-26       Impact factor: 3.090

6.  Curcumin and capsaicin regulate apoptosis and alleviate intestinal inflammation induced by Clostridioides difficile in vitro.

Authors:  Masoumeh Azimirad; Maryam Noori; Fahimeh Azimirad; Fatemeh Gholami; Kaveh Naseri; Abbas Yadegar; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-09-26       Impact factor: 6.781

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.